NCT00217139View on ClinicalTrials.gov

A Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 30, 2005

Study Completion Date

September 30, 2006

Conditions
Hepatitis C, Chronic
Interventions
DRUG

Celgosivir

Trial Locations (6)

Unknown

Calgary

Edmonton

Vancouver

Winnipeg

Halifax

London

Sponsors
All Listed Sponsors
lead

BioWest Therapeutics Inc

INDUSTRY